Introduction
Human malignant gliomas are resistant to current therapy including surgery and irradiation, as well as adjuvant chemotherapy and immunotherapy. The outcome has not been significantly improved in recent years, and median survival is still in the region of 1 year. Since there is significant immunosuppression in human glioma patients, notably in the T cell compartment, 1 glioma has become an attractive target for various types of immunotherapy. 2 Release of immunosuppressive factors such as TGF-␤ which induce T cell apoptosis 3 is one putative pathway of glioma-induced immunosuppression that has been targeted successfully in experimental glioma models by antisense strategies. 4 More recently, human glioma cells have been shown to express functional CD95 ligand at the cell surface which may also protect the tumor from cytotoxic T cell attack. 5, 6 Decorin is a small chondroitin-dermatan sulfate proteoglycan that binds various forms of active TGF-␤ through its core protein and may abrogate TGF-␤ bioactivity. 7, 8 The inhibitory effects of decorin on TGF-␤ activity have first been exploited therapeutically in experimental glomerulonephritis. 9, 10 Based on the pivotal role in the pathogenesis of malignant glioma attributed to TGF-␤, we asked whether decorin gene transfer may
Results
Generation of glioma cell sublines engineered to express human decorin Human decorin cDNA was cloned into the BCMGS neo expression plasmid 11 and transfected into the glioma cells by electroporation. Expression of the decorin transgene was assessed by Northern blot, PCR and immunoblot analysis. Strong decorin mRNA expression was readily detected in all decorin-transfected cell lines by Northern blot analysis and PCR (Figure 1a, b) . In contrast, control transfectants exhibited a decorin cDNA fragment only after two linked PCR procedures in LN-229 cells but not in the other cell lines (data not shown). Lysates from decorin-transfected cells showed strong immunoreactivity whereas neo control cells transfected contained either very little (LN-229) or no (LN-18, T98G, C6) decorin detectable by immunoblot analysis (Figure 1c , upper panel). Decorin was released in significant amounts into the supernatant of all decorin-transfected cells but was not detected in the supernatant of control transfectants (Figure 1c , lower panel). C6 decorin clone C4 was among the clones with the strongest decorin mRNA and protein expression, as well as decorin release into the supernatant. Proliferation, as assessed by determining generation times during logarithmic growth, in decorin-transfected pooled or cloned glioma cells did not differ from that of pooled control transfectants in either cell line Effects of ectopic decorin expression on TGF-␤ bioactivity and RNA and protein synthesis Next we asked whether ectopic expression of decorin in the glioma cells resulted in altered TGF-␤ activity. Supernatants from human and rat decorin-transfected glioma cells inhibited the growth of TGF-␤-sensitive CCL64 cells significantly less efficiently than supernatants from parental or neo control cells (data not shown). Specific ELISA assays were then performed to measure TGF-␤ 1 and TGF-␤ 2 release into the supernatant (Figure 3a) . TGF-␤ 2 is the dominant active form of TGF-␤ released by the glioma cells. The 
t-test). (b) Soluble proteins of whole cell lysates (upper panel) or soluble supernatant proteins (lower panel) were analyzed for immunoreactive TGF-␤ by immunoblot analysis. (c). TGF-␤ 1 or TGF-␤ 2 mRNA expression was assessed by RT-PCR. Data were normalized to the density of a coamplified ␤-actin cDNA fragment and are expressed as ratios of optical densities of TGF
highest total level of TGF-␤ 1 was found in LN-229 cells. The highest total level of TGF-␤ 2 was detected in LN-18 and T98G cells. Decorin gene transfer induced a strong reduction of active TGF-␤ 2 and total TGF-␤ 1 and TGF-␤ 2 in rat and human glioma cells. The levels of TGF-␤ 2 were reduced at least 70% (active) and 55% (total). C6 decorin clone C4 showed a reduction exceeding 90%. Immunoblot analysis using reducing SDS gels confirmed that loss of TGF-␤ protein was not due to TGF-␤/decorin complex formation, preventing antibody capture, but truely to a reduction of TGF-␤ protein (Figure 3b ). The analysis of cellular lysates which represent the intracellular pool of TGF-␤ revealed a reduction of the 12.5 kDa TGF-␤ monomer in decorin-transfected cells that was most prominent in C6 and T98G, moderate in LN-18 and hardly detectable in LN-229 cells. However, TGF-␤ levels were dramatically reduced in the supernatants of the decorin-transfected cells compared with neo controls. We assume that this loss of immunoreactivity is not a result of complex formation of decorin and TGF-␤, preventing TGF-␤ from being detected on immunoblot analysis. This is because SDS-PAGE is predicted to disrupt noncovalent protein-protein interactions, as exmplified here by the detection of the 12.5 kDa monomer of TGF-␤ rather than the 25 kDa.
That decorin not simply represses TGF-␤ bioactivity by complex formation but by altering TGF-␤ mRNA transcription or stability, was confirmed by RT-PCR (Figure 3c ) and Northern blot analysis (data not shown). Effects of ectopic decorin expression on tumor growth in vivo To assess the effects of forced decorin expression on glioma cell growth in vivo, we chose the C6 rat glioma model. Several subclones of decorin-transfected C6 cells were generated by limiting dilution cloning and characterized for decorin transgene expression by immunoblot analysis. Pooled neo or decorin transfectants and decorin clone C4, which was among the best expressing clones, were used for the in vivo experiments. In the first experiment, we injected 10 × 10 3 logarithmic-phase decorintransfected or control C6 cells into the right striatum of 6-week-old female Sprague-Dawley rats and determined tumor volumes 2 weeks later. Figure 4a shows that decorin-transfected C6 gliomas had grown to much smaller sizes than control cells. Next, 2.5 × 10 3 cells were injected and the animals killed at 2, 4 or 12 weeks. At 2 weeks, the volume of C6 decorin gliomas was again significantly reduced compared with C6 neo control animals (Figure 4b ). At 4 weeks, there was regression to small residual tumors in the decorin-transfected animals. In contrast, the control animals had developed large tumors of around 70 mm 3 (Figures 4c and 5a-c). All control animals had to be killed for progressive tumor growth at 4 weeks. One group of animals injected with decorin-transfected tumor cells was observed for 12 weeks. Here, we found a small residual tumor of approximately the same volume as after 4 weeks (Figure 4d ). We are also performing a long-term study observing six animals injected in early June 1997. These animals are still free of clinical evidence for tumor relapse at the time of the final submission of this paper (February 1998).
Persistent detection of transgene expression in vivo was confirmed by immunochemistry. Decorin was deposited mainly in the extracellular matrix. No decorin was detected in C6 control gliomas (Figure 5d and e) . Next, we asked whether regression of decorin tumors was associated with different patterns of host cell infiltration. Immunochemical studies using marker antibodies to CD45 (B and T cells), CD4 (T helper cells), CD8 (cytotoxic T cells) and CD25 (activated T cells) were performed (Figure 5f-j) . There was a greater number of infiltrating cells expressing each marker in decorin C6 tumors. Notably the number of activated T cells was increased.
To obtain further evidence for an immune-mediated regression of decorin-expressing gliomas, we injected 2.5 × 10 3 logarithmic-phase decorin-transfected or control C6 cells intrastriatally and treated the animals with the steroid, dexamethasone, which is commonly administered to human glioma patients for edema control and induces immunosuppression in these patients. Interestingly, at a dose that is clinically used to induce T cell suppression during transplantation (1 mg/kg), dexamethasone completely reversed decorin-mediated tumor regression (Figure 6a and b) . This was not due to a loss of decorin transgene expression (Figure 6c ). We also examined whether the in vivo effects of dexamethasone might be the result of direct modulation of tumor cell growth by dexamethasone and whether such actions of dexamethasone were modulated by ectopic decorin expression. Growth curves and serum response challenge experiments corresponding to the data in Figure 2 showed that dexamethasone at 1 m had no effect on growth ( Figure 6d ) and resistance to serum deprivation (data not shown) either in decorin-transfected or neo control cells.
Discussion
The present study shows that ectopic expression of the small proteoglycan, decorin, in malignant glioma cells inhibits TGF-␤ synthesis in vitro and promotes experimental glioma regression in vivo. Abrogation of gliomainduced, TGF-␤-mediated immunosuppression in the host is most likely the therapeutic principle of decorin gene transfer for malignant glioma since decorin-expressing tumors grew initially but later regressed and showed enhanced infiltration by immune cells and since the effect of decorin was nullified by coexposure to the immunosuppressive steroid, dexamethasone. Although TGF-␤ antisense strategies have also been used to limit glioma growth in experimental studies, 4 decorin gene transfer may be preferable because of its broad activity against various types of TGF-␤ which are expressed by glioma cells. 12, 13 Proteoglycans are a class of extracellular matrix macromolecules composed of a core protein covalently linked to at least one glycosaminoglycan chain. Decorin consists of a core protein of 45 kDa and one chondroitin/ dermatan sulfate chain and is expressed in human and rat embryonic and adult brain, eg in endothelial cells, vascular smooth muscle cells, the tela choroidea, the ependyma 
pooled decorin (C4, dec) or neo (neo) C6 glioma cells were injected intrastriatally and the tumor volume and the immune response determined at 4 weeks. (a-c) hematoxylin/eosin-stained coronar sections of C6 neo tumor (a, ×32), C6 decorin tumor (b, ×32; c, ×100). (d and e). Decorin expression of C6 neo (d) and C6 decorin (e) tumors detected by immunohistochemistry (×1000). (f) CD45-positive cells in C6 decorin glioma (×1000). (g-j) CD45-, CD4-, CD8-or CD25-positive cells were counted in four different coronar sections each of 4 week decorin or control tumors (n = 3). Data were normalized to control tumors and are expressed as means and s.e.m. (**P Ͻ 0.01, t-test).
and in association with myelinated fibres, and also in the cytoplasm of neurons and astrocytes. [14] [15] [16] Decorin expression is enriched in boundary regions around blood vessels, brain surface, ependyma and plexus choroideus, and is enhanced in response to brain injury. 14 The core decorin protein shows high binding affinity for TGF-␤ and has been hypothesized to act as a reservoir for TGF-␤. 17 Decorin may inhibit TGF-␤ activity by competing with TGF-␤ receptors for a common or adjacent binding site. 8 More recently, decorin has been shown to be part of a negative feed back loop that regulates TGF-␤ activity. Decorin may directly suppress the expression of TGF-␤ mRNA, 10 whereas TGF-␤ stimulates the expression of decorin mRNA and protein in several cell lines and tissues. 17 We find that decorin represses release and synthesis of TGF-␤ protein and decreases TGF-␤ mRNA in human and rat glioma cells (Figure 3a-c) . Glioma cell growth in vitro and tolerance of serum deprivation were unaffected by ectopic expression of decorin, suggesting that TGF-␤ is not a survival factor or modulator of growth for these cells in vitro. These findings contrast with several other neoplastic cell lines which were growth-inhibited by decorin in a p21-dependent manner. 18 Decorin-expressing C6 cells formed a visible tumor that regressed over time whereas control cells formed large tumors that killed their host animals within 4 weeks (Figure 4b and c) . No tumor recurrence has been noted clinically in six animals followed for 8 months now.
In an effort to elucidate the mechanism of decorininduced glioma regression, we determined that the number of infiltrating B and T cells was significantly higher in decorin-expressing tumors than in control tumors. Further, the synthetic steroid, dexamethasone, which did not differentially modulate the growth of control or decorin-transfected C6 cells in vitro, nullified the effects of decorin on tumor growth in vivo. These observations raise the possibility that decorin-mediated inhibition of TGF-␤ synthesis enhances the immunogenicity of malignant glioma cells in vivo and that decorin gene transfer holds promise as a new approach of somatic immune gene therapy for these lethal neoplasms.
Materials and methods
Cell culture and generation of glioma cell sublines engineered to express decorin LN-18 and LN-229 human malignant glioma cells were kindly provided by Dr N de Tribolet (Lausanne, Switzerland). Human T98G and rat C6 glioma cells were from ATCC (Rockville, MD, USA). The cells were grown in DMEM containing 10% FCS, 1 mm glutamine and 1% penicillin/streptomycin ('culture medium'). 19 Human decorin cDNA was cloned into BCMGS-neo. 11 BCMGSdecorin or BCMGS-neo without insert, as a control, were transfected into LN-18, LN-229, T98G or C6 cells by electroporation.
20,21
Protein detection Immunoblot analysis was performed as described previously. 19 Briefly, cells were lysed in lysis buffer (50 mm Tris-HCl, pH 8, containing 120 mm NaCl, 0.5% NP-40, 2 g/ml aprotinin, 100 g/ml PMSF, 10 g/ml leupeptin, 50 mm sodium fluoride) followed by high-speed centrifugation at 4°C for 10 min. The soluble lysates were used for TGF-␤ immunoblot analysis. For decorin labeling, an aliquot of 20 g protein was precipitated with acetone, dried and collected in digestion buffer (25 mm Tris-HCl, pH 8, 30 mm sodium acetate, 10 mm EDTA, 10 mm Nethylmaleimide, 5 mm PMSF, 0.36 mm pepstatin). Cell culture supernatants were treated accordingly. The samples were digested with chondroitinase ABC (0.1 U), 22 separated by 12% SDS-PAGE, and electroblotted to nitrocellulose. Immunodetection involved blocking for 1 h in blocking solution (10 mm Tris-HCl, pH 7.5, containing 150 mm NaCl, 0.1% Tween 20, 5% skim milk, 2% BSA), incubation with decorin or TGF-␤ antibody (1 g/ml), overnight at 4°C, and labeling with alkaline phosphatase-conjugated anti-rabbit IgG (1:10 000 in PBS/0.1% Tween 20) and nitroblue tetrazolium chloride (0.41 mm) and 5-bromo-4-chloro-3-indolyl phosphate (0.38 mm) in 200 mm Tris-HCl, pH 9.5, containing 10 mm MgCl 2 as substrate.
RNA analysis
Decorin and TGF-␤ mRNA expression were studied by Northern blot analysis and PCR. For Northern blot analysis, RNA was denatured, separated by electrophoresis on 1.5% agarose gels (20 g per lane), and transferred to nylon membranes. Nucleic acids were immobilized by ultraviolet irradiation. Membranes were prehybridized with 50% formamide, 1% SDS and 1 × SSC, and hybridized with DNA probes generated with 32 P-dCTP by random oligonucleotide priming. The blots were washed in 1 × SSC/1% SDS at 55°C for 15 min. Autoradiography films were scanned by laser densitometry. Signals obtained with an actin cDNA probe served as the control for equal loading.
For PCR analysis, mRNA was translated into cDNA using the Qiagen reverse transcriptase kit (Qiagen, Hilden, Germany). The PCR conditions were as follows: TGF-␤ assays TGF-␤ bioactivity was measured by bioassay using the TGF-␤-sensitive CCL64 mink lung epithelial cell line. 23 Briefly, 5 × 10 3 cells were adhered to 96-well plates for 24 h, washed and exposed to diluted cell culture supernatants for 36 h.
3 H-thymidine incorporation (1 Ci per well) was assessed from 24 to 36 h. Recombinant TGF-␤ served as an internal standard. To confirm the specificity of growth inhibition by TGF-␤, appropriate neutralization studies were performed with neutralizing pan-TGF-␤ antibody (25 g/ml) (R&D, Minneapolis, MN, USA). Latent TGF-␤ was activated by transient acidification. 13, 24 TGF-␤ 1 and TGF-␤ 2 were also measured by specific ELISA (R&D) using the given protocol. For total TGF-␤, supernatants were transiently acidified and diluted 1:4 in assay buffer.
In vivo studies and immunochemistry Sprague-Dawley rats (Charles River, Sulzfeld, Germany) were housed in groups of three or four under standard conditions at a temperature of 22°C and a 12 h light-dark cycle. They had free access to standard food pellets and tap water. For surgery, 12-week-old female rats weighing 250-300 g were anesthetized with pentobarbital and logarithmic-phase decorin-transfected or control C6 cells were injected stereotactically into the striatum. At 2, 4 or 12 weeks, the rats were killed. The brains were fixed in formalin/acetic-acid/methanol (1/1/8), embedded in paraffin and cut in 8-m sections for histology or 20-m sections for volumetry. Tumor volumes were determined on hematoxylin/eosin-stained sections with the MCID digitalization system (Imaging Research, Ontario, Canada). The following monoclonal primary antibodies were used for immunohistochemistry: anti-CD4 (1:200), anti-CD8 (1:500), anti-CD25 (1:500) and anti-CD45 (1:300) (Cedar Lane, Ontario, Canada). For decorin staining, the brains were frozen immediately in isopentane and stored at −80°C. Tissue sections of 8 m were cut with a Leica CM3000 cryomicrotome (Leica, Nussloch, Germany), mounted on poly-l-lysine-coated glass slides and airdried. The fixed tissue sections were pretreated with chondroitinase ABC (Boehringer, Mannheim, Germany) and stained with antidecorin antibody (1:400) (Novus Molecular, San Diego, CA, USA). Bound primary antibodies were labeled with biotinylated antimouse (CD4, CD8, CD25, CD45) or antirabbit (decorin) IgG antibodies (1:200; Camon, Wiesbaden, Germany), washed, incubated with avidin-biotin reagent (Vectastain Elite ABC peroxidase; Vector, Wiesbaden, Germany) and developed in diaminobenzidine (Sigma). For all antibodies, controls were performed by treatment with whole preimmune serum.
